A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

NCT07478302 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Unresectable Hepatocellular Carcinoma

Interventions

DRUG: SHR-2524 Injection
DRUG: Bevacizumab Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.